It is never too late to treat chronic spontaneous urticaria with omalizumab: Real-life data from a multicenter observational study focusing on elderly patients.

BACKGROUND: Chronic spontaneous urticaria might affect elderly patients, causing a serious impairment of their quality of life. The therapeutic management of the elderly patient is challenging; in fact, the first-line recommended therapy for symptom control are antihistamines, that may have interactions or increased risk of side effects in patients with comorbidities and poly-pharmacological regimen. Omalizumab is the first biological drug approved for chronic spontaneous urticaria resistant to antihistamines. Real-life data focusing on patients > 65 years old (yoa) treated with omalizumab are rare. METHODS: In our retrospective study, we evaluated the efficacy and safety of this biologic therapy in patients over 65yoa. We performed Urticaria Activity Score-7 (UAS-7) in order to evaluate the efficacy of omalizumab and the time of remission. We collected any adverse event related to the treatment. Moreover, we investigated the presence of comorbidities and their impact on the efficacy of omalizumab. RESULTS: 63 patients, with a mean age of 72.3 ± 5.6 years, range: 65-89) were enrolled. Of 63 subjects, 23 (36.5%) had an "early complete response" profile, which means the achievement of a UAS7 score of "0" within the first 7 days of therapy. The most frequent comorbidity was hypertension, which affected 26/63 (41.3%) patients; no adverse events were reported. No significant correlations were found between treatment effectiveness and comorbidities. CONCLUSIONS: omalizumab is a safe and effective therapy also in elderly patients with multiple comorbidities. This article is protected by copyright. All rights reserved.